BioCentury | Nov 2, 2017
Company News

Management tracks: Melinta, Lundbeck

...U.S. internal medicine and oncology franchises at Shire plc (LSE:SHP; NASDAQ:SHPG). Biologics and cancer company Xenetic Biosciences Inc....
BioCentury | Jun 30, 2017
Clinical News

Xenetic begins Phase II of XBIO-101 in endometrial cancer

...survival (OS). XBIO-101 is a small molecule immunomodulator and interferon inducer that increases PGR expression. Xenetic...
...excluding oncology indications (see BioCentury, Dec. 21, 2015 ). Pharmsynthez JSC (MICEX:LIFE), Saint Petersburg, Russia Xenetic Biosciences Inc....
...PFS), duration of stable disease and overall survival (OS) Status: Phase II started Milestone: NA Julian Zhu Xenetic Biosciences Inc. Progesterone...
BioCentury | Jan 6, 2017
Finance

Good riddance

...NASDAQ:VCYT) 11/2/16 $34.5 $202.2 $260.8 29% Abeona Therapeutics Inc. (NASDAQ:ABEO) 11/1/16 $42.0 $276.8 $193.8 -30% Xenetic Biosciences Inc....
BioCentury | Dec 22, 2016
Product R&D

Fever pace for Zika

...Sciences Corp. ; Sinergium Biotech ; ArgentinaMundo Sano Foundation Undisclosed vaccine Preclinical Excivion Ltd. ; Xenetic Biosciences Inc....
BioCentury | Dec 1, 2016
Clinical News

ErepoXen: Additional Ph II data

...weeks and levels were maintained in the range for the remainder of the 17-week study. Xenetic...
...cohorts of the trial (see BioCentury, Aug. 3, 2015 ). SynBio has rights to co-develop Xenetic’s...
...in Russia, while Serum Institute has co-development rights in India. SynBio LLC , Moscow, Russia Xenetic Biosciences Inc....
BioCentury | Nov 4, 2016
Financial News

Xenetic completes follow-on

...$4. Xenetic will transfer its listing to NASDAQ, effective Nov. 7. Xenetic Biosciences Inc. (OTCQB:XBIO), Lexington, Mass. Alicia Parker Xenetic Biosciences Inc....
BioCentury | Oct 17, 2016
Financial News

Xenetic amends follow-on

...raised: Up to $10 million Units: 2.5 million Price Prior: $0.24 Underwriter: Ladenburg Thalmann Note: Xenetic...
...up to $10 million. The company filed to raise up to $20 million in May. Xenetic...
BioCentury | Oct 3, 2016
Financial News

Xenetic amends follow-on

...be raised: Up to $10 million Units: TBD Price Prior: $0.24 Underwriter: Ladenburg Thalmann Note: Xenetic...
...converts into one share. The company filed to raise up to $20 million in May. Xenetic...
BioCentury | Sep 5, 2016
Company News

Excivion, Xenetic deal

...Excivion partnered to develop a Zika and dengue virus vaccine combination. The companies will use Xenetic’s...
...own resulting IP. The companies declined to disclose financial terms. Excivion Ltd. , Cambridge, U.K. Xenetic Biosciences Inc....
BioCentury | Jul 18, 2016
Financial News

Xenetic amends follow-on

...raised: Up to $15 million Units: 3 million Price Prior: $0.24 Underwriter: Ladenburg Thalmann Note: Xenetic...
...to purchase a share. The company filed to raise up to $20 million in May. Xenetic...
Items per page:
1 - 10 of 44
BioCentury | Nov 2, 2017
Company News

Management tracks: Melinta, Lundbeck

...U.S. internal medicine and oncology franchises at Shire plc (LSE:SHP; NASDAQ:SHPG). Biologics and cancer company Xenetic Biosciences Inc....
BioCentury | Jun 30, 2017
Clinical News

Xenetic begins Phase II of XBIO-101 in endometrial cancer

...survival (OS). XBIO-101 is a small molecule immunomodulator and interferon inducer that increases PGR expression. Xenetic...
...excluding oncology indications (see BioCentury, Dec. 21, 2015 ). Pharmsynthez JSC (MICEX:LIFE), Saint Petersburg, Russia Xenetic Biosciences Inc....
...PFS), duration of stable disease and overall survival (OS) Status: Phase II started Milestone: NA Julian Zhu Xenetic Biosciences Inc. Progesterone...
BioCentury | Jan 6, 2017
Finance

Good riddance

...NASDAQ:VCYT) 11/2/16 $34.5 $202.2 $260.8 29% Abeona Therapeutics Inc. (NASDAQ:ABEO) 11/1/16 $42.0 $276.8 $193.8 -30% Xenetic Biosciences Inc....
BioCentury | Dec 22, 2016
Product R&D

Fever pace for Zika

...Sciences Corp. ; Sinergium Biotech ; ArgentinaMundo Sano Foundation Undisclosed vaccine Preclinical Excivion Ltd. ; Xenetic Biosciences Inc....
BioCentury | Dec 1, 2016
Clinical News

ErepoXen: Additional Ph II data

...weeks and levels were maintained in the range for the remainder of the 17-week study. Xenetic...
...cohorts of the trial (see BioCentury, Aug. 3, 2015 ). SynBio has rights to co-develop Xenetic’s...
...in Russia, while Serum Institute has co-development rights in India. SynBio LLC , Moscow, Russia Xenetic Biosciences Inc....
BioCentury | Nov 4, 2016
Financial News

Xenetic completes follow-on

...$4. Xenetic will transfer its listing to NASDAQ, effective Nov. 7. Xenetic Biosciences Inc. (OTCQB:XBIO), Lexington, Mass. Alicia Parker Xenetic Biosciences Inc....
BioCentury | Oct 17, 2016
Financial News

Xenetic amends follow-on

...raised: Up to $10 million Units: 2.5 million Price Prior: $0.24 Underwriter: Ladenburg Thalmann Note: Xenetic...
...up to $10 million. The company filed to raise up to $20 million in May. Xenetic...
BioCentury | Oct 3, 2016
Financial News

Xenetic amends follow-on

...be raised: Up to $10 million Units: TBD Price Prior: $0.24 Underwriter: Ladenburg Thalmann Note: Xenetic...
...converts into one share. The company filed to raise up to $20 million in May. Xenetic...
BioCentury | Sep 5, 2016
Company News

Excivion, Xenetic deal

...Excivion partnered to develop a Zika and dengue virus vaccine combination. The companies will use Xenetic’s...
...own resulting IP. The companies declined to disclose financial terms. Excivion Ltd. , Cambridge, U.K. Xenetic Biosciences Inc....
BioCentury | Jul 18, 2016
Financial News

Xenetic amends follow-on

...raised: Up to $15 million Units: 3 million Price Prior: $0.24 Underwriter: Ladenburg Thalmann Note: Xenetic...
...to purchase a share. The company filed to raise up to $20 million in May. Xenetic...
Items per page:
1 - 10 of 44